Skip to main content

Table 1 Patients characteristics

From: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

 

N° (%)

386

Age (years)

 Median

68

 Range

21–88

 Elderly (≥ 70)

170 (44)

Sex

 Male

260 (67.4)

 Female

126 (32.6)

ECOG PS

 0–1

338 (87.6)

 ≥ 2

48 (12.4)

Primary tumor

 NSCLC

156 (40.4)

 Melanoma

163 (42.2)

 Renal cell carcinoma

59 (15.3)

 Others

8 (2.1)

No. of metastatic sites

 ≤ 2

219 (56.7)

 > 2

167 (43.3)

Type of anti-PD-1/PD-L1 agent

 Pembrolizumab

120 (31.1)

 Nivolumab

253 (65.5)

 Atezolizumab

10 (2.6)

 Others

3 (0.8)

Treatment line of immunotherapy

 First

137 (35.5)

 Non-first

249 (64.5)